Damora Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months EndedMarch 31, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Cash flows from operating activities | ||||
| Net loss | $(27,783) | $(2,533) | ||
| Adjustment to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation of equipment | 5 | 5 | ||
| Stock-based compensation | 3,134 | 179 | ||
| Issuance of common stock in connection with vesting of restricted stock units | — | 29 | ||
| Amortization of right of use lease asset | 63 | 3 | ||
| Accretion of lease liability | — | 1 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | 290 | (323) | ||
| Other assets, noncurrent | — | (151) | ||
| Accounts payable | 375 | (23) | ||
| Accrued expenses and other current liabilities | 3,597 | 377 | ||
| Paramora warrant obligation | 4,984 | — | ||
| Related party accounts payable and other current liabilities | (5,209) | — | ||
| Other liabilities, noncurrent | (54) | (3) | ||
| Net cash used in operating activities | $(20,598) | $(2,439) | ||
| Cash flows from financing activities | ||||
| Proceeds from issuance of stock in connection with offering, net of issuance costs | 295,497 | — | ||
| Proceeds from issuance of common stock in connection with stock option exercise | 424 | — | ||
| Net cash provided by financing activities | $295,921 | $ | - | |
| Net increase (decrease) in cash and cash equivalents | $275,323 | $(2,439) | ||
| Effect of exchange rate changes on cash and cash equivalents | (48) | 203 | ||
| Cash and cash equivalents, beginning of year | 257,624 | 14,175 | ||
| Cash and cash equivalents, end of year | $532,899 | $11,939 | ||
| Supplemental disclosures of cash flow information: | ||||
| Cash paid for taxes | $ | - | $2 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.